Georgia-Mennarini Group, first class of competitive immunoassistant GIM-621 Global Exclusive License and Cooperation Agreement signed

Summary

GIM-621 is the first advanced stage of its class to be used in a range of malignant cancers. Georgia will receive $45 million in contract money and short-term payments under contracts totaling up to $1.1 billion, and will receive royalty separately. Italy Florence and Maryland Gaithersburg, October 23, 2026 — Global pharmaceutical and diagnostic company Menari Group Menari...